Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Servier enters agreement with and Scandicure to conduct research in the field of metabolic diseases

April 9, 2018

Phase II study of FP-101 recruiting participants

April 9, 2018

New phase IIb study explores use of sepranolone for premenstrual dysphoric disorder

April 6, 2018

European Commission grants marketing authorization to Lamzede

April 6, 2018

Lilly and Sigilon collaborate on encapsulated cell therapies for type 1 diabetes

April 5, 2018

FDA allows IND for phase Ib/IIa study of AG-019 for early onset type 1 diabetes

April 5, 2018

Rhythm acquires rights to Takeda GOAT inhibitor for Prader-Willi syndrome

April 4, 2018

Numerate patents novel FFAR4 agonists

April 3, 2018

Prometic Life Sciences offers new data from phase II study of PBI-4050 in Alstrom syndrome

March 29, 2018

Lanadelumab submissions in E.U. and Canada accepted for review

March 29, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 16, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...